Neurodegenerative diseases are a devastating group of disorders that can be difficult to accurately diagnose. Although these disorders are difficult to manage owing to relatively limited treatment options, an early and correct diagnosis can help with managing symptoms and coping with the later stages of these disease processes. Both anatomic structural imaging and physiologic molecular imaging have evolved to a state in which these neurodegenerative processes can be identified relatively early with high accuracy. To determine the underlying disease, the radiologist should understand the different distributions and pathophysiologic processes involved. High-spatial-resolution MRI allows detection of subtle morphologic changes, as well as potential complications and alternate diagnoses, while molecular imaging allows visualization of altered function or abnormal increased or decreased concentration of disease-specific markers. These methodologies are complementary. Appropriate workup and interpretation of diagnostic studies require an integrated, multimodality, multidisciplinary approach. This article reviews the protocols and findings at MRI and nuclear medicine imaging, including with the use of flurodeoxyglucose, amyloid tracers, and dopaminergic transporter imaging (ioflupane). The pathophysiology of some of the major neurodegenerative processes and their clinical presentations are also reviewed; this information is critical to understand how these imaging modalities work, and it aids in the integration of clinical data to help synthesize a final diagnosis. Radiologists and nuclear medicine physicians aiming to include the evaluation of neurodegenerative diseases in their practice should be aware of and familiar with the multiple imaging modalities available and how using these modalities is essential in the multidisciplinary management of patients with neurodegenerative diseases.
After completing this journal-based SA-CME activity, participants will be able to:
■ List the recommended MRI sequences commonly employed in structural MRI analysis and identify region- and lobar-specific patterns of volume loss and other pertinent imaging findings.
■ Recognize the different nuclear medicine imaging agents and the imaging patterns of the most common neurodegenerative diseases.
■ Contribute to a multidisciplinary approach in the workup of neurodegenerative disorders.
Introduction
Neurodegenerative diseases are a collection of diverse, devastating, and increasingly common processes that can cause significant distress and expense. The most common of these, Alzheimer disease, is estimated to affect 5.8 million people in the United States, with a projected increase to 14 million by 2050, as per the Alzheimer’s Association (1). In 2019, the cost to the nation from Alzheimer disease and other dementias is estimated to be $290 billion. Although different forms of management exist for these disease processes, treatment efficacy relies on early diagnosis, and overall prognosis remains poor. Diagnosis relies heavily on constellations of clinical findings, which can be difficult to detect and nonspecific. Moreover, patients are typically diagnosed later in the disease process (2), and many patients and families have difficulty accepting or identifying these diagnoses on clinical grounds. Definitive objective diagnosis is only possible through brain biopsy or autopsy analysis.
Neuroimaging is advancing to a state in which accurate and objective diagnosis and evaluation of these neurodegenerative disorders is possible. The common availability of high-spatial-resolution MRI has made detailed analysis of sometimes relatively subtle structural changes possible, and the implementation of pathophysiology-specific radiotracers in nuclear medicine allows visualization of the underlying mechanisms of these disease processes. The radiologic and nuclear medicine modalities are complementary, and by using an integrated approach with the clinical presentation, early diagnosis can be achieved, giving patients and families an opportunity to confront the disease and start earlier management.
Structural Imaging
Traditionally the role of neuroimaging in dementia has been to exclude other possible causes that result in cognitive impairment, such as intracranial hemorrhage or space-occupying lesions (Fig 1). Widespread availability and recent advances have expanded the role of structural imaging in the assessment of neurodegenerative disorders. Structural imaging can support the clinical diagnosis of dementia and mild cognitive impairment, and many trials are investigating its value as a marker for disease progression and as outcome measures for disease-modifying treatments (3).
Knowledge of the relevant anatomic structures is a prerequisite to performing structural assessment. Often, the initial step is to assess for global cerebral and cerebellar volume loss. This should be followed by a more in-depth assessment for region- or lobar-specific patterns of volume loss, as these patterns are critical in differentiating the neurodegenerative diseases. Many of the structures in the limbic system, such as the hippocampus and entorhinal cortex (important for memory function), are directly involved in the common neurodegenerative disorders and are vital to interpreting anatomic imaging (4). Another important area to evaluate is the precuneus (medial parietal lobe), which is best evaluated on sagittal T1-weighted MR images (Fig 2). Detection of precuneus involvement also has potential implications in early-onset Alzheimer disease (6).
In routine clinical practice, the assessment is usually qualitative, which may lead to ambiguity and interobserver variability. A few quick, reproducible, and cost-effective semiquantitative scales have been described, particularly for Alzheimer disease, such as the medial temporal atrophy scale by Scheltens et al (7,8) on which patients are scored on the basis of hippocampal formation and the surrounding cerebrospinal fluid spaces. Urs et al (9) expanded on this and described the visual rating system, a system in which patients are scored of the basis of the degree of atrophy of the hippocampus, entorhinal cortex, and perirhinal cortex (Fig 3) (9). Specialized software programs that can provide volumetric analysis are also available for quantitative assessment.
When evaluating patients with suspected dementia at our institution, we perform routine MRI brain sequences, including diffusion-weighted imaging, to help identify infarcts and hypercellular lesions; susceptibility-weighted imaging to identify blood products; and T2-weighted fluid-attenuated inversion-recovery (FLAIR) imaging to identify edema, encephalomalacia, and white matter changes.
It is important to perform a high-spatial-resolution volumetric T1-weighted sequence with multiplanar reformation and a T2-weighted coronal sequence. The T2-weighted coronal sequence should be performed perpendicular to the long axis of the hippocampus for evaluation of the mesial temporal lobe (Fig 4) (10).
Other neurodegenerative disorders such as vascular dementia, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and multiple system atrophy, which are discussed in the following sections, can be corroborated at structural imaging.
Molecular Imaging
Multiple nuclear medicine imaging agents exist for neurodegenerative processes, the major ones including PET with fluorine 18 (18F) fluorodeoxyglucose (FDG) and amyloid-β and SPECT with iodine 123 (123I) ioflupane. Additional new agents are under development, including τ-based PET for imaging tauopathies.
FDG PET
FDG is by far the most common contrast agent used in modern PET. The positron-emitting 18F substitutes a hydroxyl group on normal glucose, resulting in a molecule that is taken up by standard glucose transporters. This molecule is then phosphorylated and trapped in cells, resulting in accumulation in metabolically active cells. This creates the metabolism map that is most commonly used in oncologic PET. Additionally, as the brain is almost entirely glucose dependent and metabolically active, it allows visualization of the functioning cerebral cortex. Although this obscures evaluation when looking for metastatic disease, it can be used to visualize areas that are either hyper- or hypofunctioning.
In neurodegenerative diseases, the underlying pathophysiology causes damage to cerebral tissues and alters their normal metabolism. In structural imaging, this causes visible atrophy once enough damage has been done. As FDG allows visualization of metabolic derangement, it can demonstrate areas that are not functioning properly (Fig 5).
Although lack of functioning is nonspecific, it can show the distribution of metabolic derangements, which allows differentiation of disease processes in the same manner as that of structural MRI. FDG PET and MRI are useful when used in conjunction to confirm findings and potentially identify early abnormalities that have not yet manifested in structural change (11).
The imaging protocol shares some similarities with traditional oncologic PET, and guidelines adapted from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) procedure standards can be found in Table 1 (12). Similar fasting and dietary restrictions are necessary with monitoring of blood glucose levels on the day of the examination. In addition to activity limitation and environmental control after injection, patients must have little to no external stimuli to avoid activation of different areas of the cerebral cortex. For example, at our institution patients are typically given eye covers (similar to those used for sleeping on flights) to avoid occipital lobe stimulation.
Table 1. SNMMI Recommendations and Radiopharmaceutical Information for 18F-FDG PET
Amyloid-β PET
A relatively new group of contrast agents exists that allows visualization of abnormal amyloid aggregation. Although the original agent was carbon 11–Pittsburgh compound B, the current major radiopharmaceuticals in this group are all tagged with 18F and include 18F-florbetapir, 18F-florbetaben, and 18F-flutemetamol. These are now commercially available under the names Amyvid (Eli Lilly, Indianapolis, Ind), NeuraCeq (Piramal Group, Mumbai, India), and Vizamyl (GE Healthcare, Chicago, Ill), respectively. A similar mechanism is responsible for the distribution of these agents, wherein the molecules bind to β-amyloid fibrils and plaques. These agents are fairly nonspecific and will also bind to other amyloid deposits, with research being conducted on the clinical utility of working up systemic amyloidosis (13).
At neurologic imaging, normal white matter takes up these agents. The mechanism is not well understood, but research suggests it may bind to myelin-binding proteins and could be used in the workup of demyelinating diseases (14).
At β-amyloid imaging, areas of increased cortical uptake are considered abnormal and correspond to cortical deposition of β-amyloid plaques. An internal control is used to establish a normal uptake pattern, with the cerebellum typically used to compare gray-white differentiation, as the cerebellum rarely has abnormal amyloid accumulation (Fig 6) (15).
Although cases with extensive uptake are easily identified, more subtle areas of uptake can be difficult to identify. Also, research has shown that early-phase amyloid imaging can have a distribution similar to that depicted at FDG PET, allowing for metabolic information to be obtained using multiphase imaging (16).
The imaging protocol for amyloid PET is simple, and Table 2 details the guidelines adapted from the SNMMI procedure standards (17). Imaging is performed 30–120 minutes after injection, depending on the dose and radiotracer used, and no special considerations are necessary before injection or during the waiting period.
Table 2: SNMMI Recommendations and Radiopharmaceutical Information for 18F-Amyloid PET
123I-Ioflupane SPECT
Parkinsonian-type diseases share a similar pathophysiology, with loss of dopaminergic neurons. These neurons are predominantly clustered in the substantia nigra and contain axons that extend into the corpus striatum, with synapses that rely on dopamine to be released to carry out their functions. Dopamine then needs to be collected again by the presynaptic terminal, which uses a transporter called the dopamine transporter (Fig 7). The chosen target for this transporter is 123I-ioflupane, commercially referred to as DaTScan (GE Healthcare). This agent allows visualization of the active synapses in the corpus striatum. Parkinsonian diseases cause destruction of dopaminergic neurons, which causes wallerian degeneration of the axons and loss of the dopaminergic synapses, resulting in decreased or absent radiotracer accumulation at the site of these synapses in the corpus striatum. Normal distribution has a comma appearance, with the curved uptake in the caudate heads and putamina. Patients with parkinsonian diseases begin with loss in the putamina, resulting in a period appearance, which can progress to almost complete loss of uptake (Fig 8).
There are a few considerations before beginning ioflupane imaging. Table 3 describes the guidelines adapted from the SNMMI procedure standards (18). Pharmaceuticals with a heavy α-adrenergic effect can severely impair ioflupane binding. Since this agent uses 123I, unwanted radioactivity can accumulate in the thyroid gland. This can be prevented by administering oral iodine or potassium perchlorate to saturate and protect the thyroid.
Table 3: SNMMI Recommendations and Radiopharmaceutical Information for 123I-Ioflupane SPECT
τ-based PET
One of the newest imaging agents available uses the binding of τ proteins. These agents bind to intra- and extracellular neurofibrillary tangles. Although many are currently in development, the agent with the largest amount of traction was referred to as 18F-AV-1451 during research but now has the name 18F-flortaucipir. These agents have good target-to-background ratios, with healthy patients exhibiting minimal uptake. However, off-target binding can sometimes be depicted in the basal ganglia in otherwise healthy patients (19). The accumulation of a radiotracer should correspond to the pathologic areas of abnormal τ accumulation, such as within the hippocampal body and precuneus in cases of Alzheimer disease. Because of the good target-to-background ratio, even low-level uptake at the mesial temporal lobes and entorhinal cortices can represent early pathologic changes of Alzheimer disease corresponding to Braak stages I and II.
Certain tauopathy-type diseases demonstrate abnormal activity in the affected areas (Fig 9). Tauopathies predominantly accumulate two abnormal types of τ protein, three repeat (3R) and four repeat (4R). Research demonstrates that diseases that accumulate both 3R- and 4R-type misfolded τ proteins result in the most radiotracer accumulation, examples of which include Alzheimer disease, chronic traumatic encephalopathy, and progressive supranuclear palsy (20). Research also demonstrates that the distribution of radiotracer uptake can also be helpful in differentiating the underlying cause of neurocognitive impairment. For example, while Alzheimer disease demonstrates uptake corresponding to the areas outlined by the Braak staging system, chronic traumatic encephalopathy has been shown to demonstrate diffuse uptake along the gray-white junction related to the underlying cause of chronic injury and shear forces at these locations (21).
Computer-assisted Quantitative Evaluation
In nuclear medicine, quantification of uptake is possible based on the counts in a specific area. Standardized uptake values as used in oncologic PET are difficult to use, and the extensive data required to truly standardize the measurements do not yet exist. However, comparing uptake to that in known normal examinations can allow relative quantitative regional measurements and generate maps corresponding to the standard deviations of uptake from normal examinations. Datasets containing numerous normal examinations are generated, and through machine learning, algorithms are able to learn the normal distribution of uptake. This algorithm can be applied to abnormal cases and generate color maps to visually demonstrate areas that have abnormally decreased uptake that fall outside a specified set of standard deviations below a certain z score (Fig 10), in which the z score reflects the number of standard deviations from those of normal uptake, similar to that in a dual-energy x-ray absorptiometry examination. This functionality exists in multiple available software packages for both PET and SPECT. This technique can be helpful for identifying subtle areas of abnormality (22), and it can be used in research protocols as a method of quantification for a more regimented comparison.
Pathophysiology of Neurodegenerative Diseases
The various neurodegenerative diseases are characterized by unique disturbances on the histopathologic level. Although the exact mechanisms that result in the development of these diseases are mostly unknown, these entities can be loosely grouped into categories that share an over-arching similar histopathology. This is imprecise and in some cases there is significant crossover, but recognizing the basis of these changes is essential for understanding which molecular imaging modalities can be applied to which disease. The three that relate the most to imaging are the concept of tauopathies, β-amyloid accumulation, and α-synucleinopathies.
Tauopathies are characterized by the aggregation of misfolded τ proteins. The τ proteins stabilize neural microtubules in the normal brain. When misfolded, they clump and destabilize microtubules, causing dissolution and the formation of neurofibrillary tangles. Entities that fall into this group include frontotemporal lobar degeneration (FTLD), corticobasal degeneration, and progressive supranuclear palsy. As mentioned previously, misfolded proteins come in two main varieties, 3R and 4R isoforms, and different disease processes accumulate different isoforms (20). Interestingly, chronic traumatic encephalopathy also results in the abnormal accumulation of 3R and 4R τ aggregates (23). Alzheimer disease also has 3R and 4R τ aggregates but is considered a secondary tauopathy given the equal or greater representation of β-amyloid accumulation in the disease process (24). These agents can be imaged by τ agents such as 18F-AV-1451 (or 18F-flortaucipir).
β-amyloid accumulation is one of the primary aberrations in patients with Alzheimer disease. Extracellular amyloid plaques are the classic finding (Fig 11), although evidence suggests intracellular amyloid accumulation also plays a role (25). These plaques can be detected by amyloid-specific agents. Although Alzheimer disease is typically the entity defined by amyloid plaques, amyloid accumulation (and therefore abnormal amyloid nuclear imaging) can be depicted in other entities as well (26–28).
Abnormal accumulation of α-synuclein is depicted in cases of neurodegenerative disease with Lewy body inclusions (Fig 12). The diseases making up the α-synucleinopathy subgroup are Parkinson disease, dementia with Lewy bodies (DLB), and multiple system atrophy. Clinically, these entities demonstrate parkinsonian symptoms with damage to the basal ganglia and visual cortices. Because of the damage to the basal ganglia, these are typically abnormal on 123I-ioflupane SPECT images. Of interest, α-synuclein also accumulates in the gastrointestinal tract, resulting in gastrointestinal symptoms (29).
Alzheimer Disease
Alzheimer disease is the prototypical neurodegenerative disease. This is by far the most common neurodegenerative disease, accounting for the majority of patients with dementing disorders. This translates into a total disease incidence of as high as 20 million, with 5 million new diagnoses each year. Per total population, this accounts for nearly 5% of all individuals 65 years of age or older (30). Some estimates are even higher at 6%–10% (31). Annual costs worldwide in 2015 were estimated at over $950 billion, with a cost per patient of $19 000 (32).
Histopathologically, this disease is characterized by the accumulation of β-amyloid plaques and misfolded τ protein neurofibrillary tangles. β-amyloid deposition patterns and the significance of amyloid burden to clinical symptoms is not well understood (33), but τ protein deposition does follow a more predictable pattern, which is classified by the Braak staging system (34). This is broken down into six stages, where stages I and II show uptake at the entorhinal cortex, III and IV are in the limbic system and hippocampus, and V and VI are spread throughout the rest of the cortex (Fig 13). These misfolded τ proteins are a mixture of 3R and 4R isoforms.
Clinically, Alzheimer disease begins as mild cognitive impairment, which slowly progresses to outright dementia. Diagnostic criteria are complex, but generally diagnosis requires an insidious onset (rapid-onset dementia is concerning for other causes, such as Creutzfeldt–Jakob disease), amnesia with loss of short-term recall, language deficits starting with word-finding abnormalities, and loss of spatial orientation. Importantly, these symptoms must be enough to impair daily life (35). The slow onset and capability to compensate contribute to difficulty and delay in diagnosis. Additionally, there are atypical variants that exhibit symptoms more similar to those of FTLD, as discussed in the next section.
The earliest atrophic changes in Alzheimer disease on structural MR images are depicted in the entorhinal cortex (Brodmann area 28), and eventually in the hippocampus (36). The atrophic changes then typically follow a predictable pattern following the pathologic Braak staging system involving the neocortex, particularly the precuneus.
The typical pattern of hypometabolic activity in Alzheimer disease on 18F-FDG PET images involves the parietotemporal region, precuneus, and posterior cingulate gyrus, with sparing of the sensorimotor strips and occipital region, which usually corresponds to the atrophic changes depicted on structural images (Fig 14).
However, in some cases the molecular imaging findings may show advanced hypometabolic activity without region-specific changes at structural imaging (Fig 15). Many Alzheimer disease variants, such as language, visual, and dysexecutive variants, are currently under investigation, and they tend to follow the general distribution as previously described, with few relatively distinct areas of uptake (37).
Amyloid imaging agents show abnormal cortical uptake corresponding to the β-amyloid accumulation. Classic uptake is usually symmetric and diffuse throughout the cortical gray matter, with sparing of the cerebellum, which is used as an internal control (Fig 16). Studies have shown relatively little variation in uptake across Alzheimer disease and its variants, and amyloid accumulation irrespective of the burden may result in increased vulnerability for early-onset Alzheimer disease (38). Although amyloid deposition can be diagnosed in patients without clinical dementia, negative amyloid uptake has a good negative predictive value for Alzheimer disease. The τ imaging agents show uptake distribution following the patterns described in the Braak staging system, which is readily detectable given the overall minimal normal levels of uptake (39).
Dementia with Lewy Bodies
DLB is the second most common primary dementing neurodegenerative disorder after Alzheimer disease. Estimates predict 10%–25% of dementia cases are related to DLB (40). However, it is likely that this specific disorder is underdiagnosed owing to a general lack of awareness and misdiagnosis as traditional Alzheimer disease.
DLB is defined histopathologically by the aggregation of Lewy bodies, which is similar to that which occurs in Parkinson disease. These Lewy bodies are clumps of misfolded α-synuclein proteins, which create inclusions that can be visualized under a microscope. There is a separate Braak staging system for Lewy body aggregation, which was originally described in Parkinson disease. This suggests that Lewy body progression starts peripherally, migrating to the pons and midbrain, then eventually spreading through the supratentorial regions. Because of the spread of involvement, this results in damage to dopaminergic neurons centered at the substantia nigra and basal ganglia (41).
Clinically, DLB is characterized by progressive cognitive decline accompanied by parkinsonian and visual symptoms, frequently visual hallucinations. This is similar to Parkinson disease dementia, which is differentiated from DLB by the order of onset, in which parkinsonism without cognitive decline appears first, followed by dementia (42). Similar to Parkinson disease, there are significant gastrointestinal symptoms, including constipation, nausea, vomiting, and gastroparesis. These symptoms are attributed to Lewy body deposition within enteric neurons throughout the gastrointestinal tract.
Structural imaging findings are less conspicuous and nonspecific in DLB compared with those of Alzheimer disease and FTLD. There is relative preservation of the mesial temporal lobe and less severe atrophy of the hippocampus compared with those of Alzheimer disease (42). Additionally, the swallow tail sign has been described for the normal appearance of nigrosome 1 in the substantia nigra on axial high-spatial-resolution susceptibility-weighted images. Nigrosome 1 demonstrates high signal intensity on axial susceptibility-weighted images and is surrounded by low signal intensity, resembling a swallow’s tail. Absence of the normal high signal intensity (absent swallow tail sign) is reported to have high diagnostic utility in parkinsonian neurodegenerative diseases and can be supportive of a DLB diagnosis (43).
In patients with DLB, 18F-FDG PET images show asymmetric decreased activity in the frontotemporal lobes similar to that depicted in Alzheimer disease; however, there is preserved metabolism of the posterior cingulate cortex, resulting in the so-called cingulate island sign (Fig 17). Alzheimer disease almost invariably involves the posterior cingulate gyrus, and this is a useful differentiating factor (44). There is hypometabolism of the occipital lobes, which is helpful to differentiate DLB from typical Alzheimer disease.
123I-ioflupane SPECT images will show decreased striatal uptake in DLB, beginning in the putamen and resulting in a period appearance with sparing of the caudate head (Fig 18), in contradistinction to that in healthy patients and patients with Alzheimer disease, in which there is a comma appearance of the normal striatal uptake. This can be asymmetric and later in the disease can progress to also involve the caudate head. This can be helpful to corroborate findings depicted on MR and FDG PET images.
Unfortunately, β-amyloid imaging may not adequately differentiate DLB from Alzheimer disease, as many cases may exhibit significant abnormal β-amyloid accumulation. However, Parkinson disease dementia has been shown to exhibit lower levels of abnormal β-amyloid uptake (26,27). Neither DLB nor Parkinson disease dementia should have definite abnormal uptake at 18F-AV-1451 τ-based imaging in a Braak staging system–type distribution.
Frontotemporal Lobar Degeneration
FTLD is a term applied to a number of similar tauopathies that result in destruction of the frontal and temporal lobes. The entity referred to as Pick disease falls into this category. Once thought of as rare entities, these diseases appear to have a higher prevalence than was previously assumed (45,46). This is likely due to increased awareness and improved diagnostic criteria. Alzheimer disease and DLB are accepted as having a higher overall prevalence, with this group representing the third most common group of dementing disorders in patients over 65 years of age and the second most common group in patients under 65 years of age (47).
The histopathology of these diseases demonstrates the accumulation of abnormal τ proteins in the affected areas. Depending on the subtype, different isoforms of the τ protein are involved, with most entities having either a predominant 3R- or 4R-type isoform. Although the classic Pick disease has Pick bodies, many of the other subtypes do not demonstrate this typical appearance (48).
The clinical presentation is divided into two main groups: behavioral-variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA). All forms of frontotemporal dementia have both marked behavioral changes and decrease in overall cognitive function. The bvFTD type is characterized by marked behavioral changes as the first and most clinically obvious symptoms. PPA is defined by difficulties in language function with three main variants: semantic variant (impaired naming and comprehension), nonfluent variant (halting, interrupted speech), and logopenic variant (impaired word retrieval with word-finding pauses) (47).
Most research into the use of structural imaging for FTLD has been aimed at improving differentiation from other neurodegenerative disorders and differentiating between the subtypes (49). All the subtypes show predominant frontotemporal atrophy (Fig 19), with the severely affected regions showing knifelike gyri owing to the marked loss of brain volume. There is relative sparing of the parietal and occipital lobes. In bvFTD, there is volume loss in the frontal and temporal lobes, with asymmetric involvement of the anterior temporal lobes, prefrontal cortices, the insula, anterior cingulate, striatum, and thalamus (50). In PPA, there is asymmetric anteroinferior temporal lobe atrophy, with left-sided atrophy more common than the right (51).
The typical pattern of hypometabolic activity on 18F-FDG PET images usually follows the structural changes and shows asymmetric decreased activity in the frontal and temporal lobes. Classically, there is comparative sparing of the precuneus and occipital lobes, differentiating FTLD from Alzheimer disease and DLB (Fig 20).
β-amyloid PET can be used to differentiate between Alzheimer disease and FTLD, as amyloid deposition is not part of the FTLD spectrum. A few studies have shown amyloid positivity in FTLD, which may be secondary to false-positive results, coexistent FTLD and Alzheimer pathology, and atypical variants of Alzheimer disease mimicking FTLD (52).
The role of τ imaging is unclear at this time. 18F-AV-1451 appears to be relatively insensitive to FTLD, as most of these entities are not a mixture of 3R and 4R (20). However, there are multiple other τ candidates being developed, and further research is necessary to assess their utility in FTLD.
Vascular Dementia
Although not truly a primary neurodegenerative disease, vascular-induced dementia is common and is important to consider in the differential diagnosis for patients with neurocognitive impairment. It is accepted as being the second overall most common cause of clinical dementia (53). The underlying pathophysiology is related to neural loss from impaired circulation, the most classic being multiple ischemic infarcts. The entity referred to as Binswanger disease, or subcortical arteriosclerotic encephalopathy, falls into this category.
Clinical diagnosis can be difficult, as the range of symptoms and onset vary depending on the involved regions. Development of impaired cognition with focal neurologic deficits is fairly easy to identify clinically, but if the vascular insults are small and cumulative over a long time, this can be difficult to differentiate from a primary dementing disorder. The classically taught presentation is a stepwise dementia with punctuated time intervals of progressively worsening cognition, although this is variable (54).
MR images show typical findings of vascular insults, such as encephalomalacia from multiple vascular territory infarcts, strategically placed infarcts, and white matter changes (Fig 21) (55). There are usually secondary signs of volume loss with enlargement of the ipsilateral sulci and lateral ventricle. Numerous sets of diagnostic criteria have been proposed, such as the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), and National Institute of Neurological Disorders and Stroke (NINDS)–Association Internationale pour la Recherche et l’Enseignement en Neurosciences (AIREN) criteria (56,57). 18F-FDG PET shows findings of hypometabolism correlating to abnormal areas at structural imaging (Fig 22).
Other Dementing Disorders
Although the previously discussed disorders are some of the most common dementing disorders, there are many other diseases that should be considered. Normal pressure hydrocephalus is relatively common and can sometimes be confused clinically with other forms of dementia. This has characteristic imaging findings that should be identified at structural imaging to direct the patient toward appropriate management (Fig 23). In patients with rapidly progressive dementia, the diagnosis of Creutzfeldt–Jakob disease should be considered, and relatively characteristic imaging findings at structural imaging should guide the diagnosis (Fig 24). Patients with parkinsonian symptoms, the Parkinson-plus diseases, should be considered, including multiple system atrophy, corticobasal degeneration, and progressive supranuclear palsy.
Patient Workup, Algorithm, and Recommendations
In the workup for dementia and neurodegenerative processes with neuroimaging, it is important to have a good relationship with referring physicians and an algorithm for recommendations. Triaging patients to receive dedicated imaging frequently occurs with clinical assessment, although these patients can be identified by the radiologist at CT or MRI performed for other indications. For this reason, it is important that all radiologists have a working knowledge of the basic findings to allow identification of these patients, so they can receive adequate medical evaluation and treatment. Accurate workup also requires a thorough knowledge of the appearance of different processes at different imaging modalities (Table 4).
Table 4: Pathophysiology and Imaging Findings of Neurodegenerative Diseases
Workup can begin with either identification by the radiologist and nuclear medicine physician or direct referral from a clinician. At our institution, we recommend that the first step in evaluation should be performing dedicated structural imaging for all patients with a suspected dementing neurodegenerative disorder. This allows the identification and exclusion of other processes, and in some cases may be highly supportive of a neurodegenerative diagnosis. We also typically perform FDG PET to further elucidate any region-specific abnormalities, although patients presenting with clinically apparent parkinsonian symptoms may benefit from an initial ioflupane examination. For many patients, the combination of structural imaging and FDG PET allows identification of a particular disease process. For those patients in whom the appearance is more ambiguous, β-amyloid imaging is recommended. Amyloid deposition, although not specific, can be helpful by using its negative predictive value to increase the likelihood of a non–Alzheimer disease diagnosis. Although not yet widely available, dedicated τ imaging will likely play a similar role, perhaps with greater sensitivity and specificity than those of amyloid imaging. If FDG PET imaging has findings suggestive of DLB, performing imaging with ioflupane is recommended for confirmation (Fig 25).
Conclusion
Dementing neurodegenerative disorders are a diverse and clinically devastating group of diseases. It is important that practicing radiologists and nuclear medicine physicians have knowledge of the findings and available imaging modalities to appropriately identify these diseases and triage these patients. Although treatment of many of these disorders is difficult with the end prognosis still being poor, there are differences in treatment and clinical expectations that are important for management. Moreover, having the ability to offer objective evidence for a particular diagnosis can be helpful both for physicians in identifying and excluding other causes and for patients and families so they can be correctly informed and prepared to avoid unnecessary hardship, both emotionally and financially. This is particularly important given the high and increasing prevalence of these diseases, and radiologists and nuclear medicine physicians are an integral component in providing valuable service to these patients and families.
Acknowledgments
The authors will like to give special acknowledgment to Raymond James LaRue, Gainesville, Fla, for his contribution of original artwork (Figures 2, 7, and 13). The authors would like to give special acknowledgment to Jeffrey Sachs, MD, Winston-Salem, N.C., for contributing the images used in Figure 8. The authors would like to give special acknowledgment to Warren Barker, Miami Beach, Fla, and Benoit Giasson, PhD, Gainesville, Fla, for contributions of original pathology slides (Figures 11, 12) for work that was supported by the National Institute on Aging Grant, number 5 P50 AG0477266021, Florida Alzheimer’s Disease Research Center (Todd Golde, PI).
R.D. supported by the National Institute on Aging (5 P50 AG0477266021).
Presented as an education exhibit at the 2018 RSNA Annual Meeting.
For this journal-based SA-CME activity, the authors, editor, and reviewers have disclosed no relevant relationships.
2. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord2009;23(4):306–314.
5. Shen Q, Loewenstein DA, Potter E, et al. Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement2011;7(4):e101–e108.
7. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry1992;55(10):967–972.
9. Urs R, Potter E, Barker W, et al. Visual rating system for assessing magnetic resonance images: a tool in the diagnosis of mild cognitive impairment and Alzheimer disease. J Comput Assist Tomogr2009;33(1):73–78.
10. Albert M, DeCarli C, DeKosky S, et al. The Use of MRI and PET for Clinical Diagnosis of Dementia and Investigation of Cognitive Impairment: A Consensus Report—Report of the Neuroimaging Work Group of the Alzheimer’s Association. Published 2005. https://www.alz.org/national/documents/imaging_consensus_report.pdf. Accessed January 9, 2019.
11. Dukart J, Mueller K, Horstmann A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One2011;6(3):e18111.
13. Mestre-Torres J, Lorenzo-Bosquet C, Cuberas-Borrós G, et al. Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis. Amyloid2018;25(2):109–114.
22. Kakimoto A, Kamekawa Y, Ito S, et al. New computer-aided diagnosis of dementia using positron emission tomography: brain regional sensitivity-mapping method. PLoS One2011;6(9):e25033.
25. Wang S, Mims PN, Roman RJ, Fan F. Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer’s Disease?J Alzheimers Parkinsonism Dement2016;1(2):007.
26. Shimada H, Shinotoh H, Hirano S, et al. β-Amyloid in Lewy body disease is related to Alzheimer’s disease-like atrophy. Mov Disord2013;28(2):169–175.
28. Tan RH, Kril JJ, Yang Y, et al. Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement (Amst)2017;9:10–20.
29. Yan F, Chen Y, Li M, et al. Gastrointestinal nervous system α-synuclein as a potential biomarker of Parkinson disease. Medicine (Baltimore)2018;97(28):e11337.
30. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci2009;11(2):111–128.
34. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl)2006;112(4):389–404.
35. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011;7 (3):263–269.
38. Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. Brain2010;133(Pt 2):512–528.
39. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain2016;139(Pt 5):1539–1550.
40. Yang SK, Chen W, Su CH, Liu CH. Incidence and Comorbidity of Dementia with Lewy Bodies: A Population-Based Cohort Study. Behav Neurol2018;2018:7631951.
41. Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther2014;6(4):46.
43. Shams S, Fällmar D, Schwarz S, et al. MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?AJNR Am J Neuroradiol2017;38(9):1737–1741.
45. Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain2006;129(Pt 11):3051–3065.
48. Cairns NJ, Bigio EH, Mackenzie IRA, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl)2007;114(1):5–22.
50. Schroeter ML, Raczka K, Neumann J, Yves von Cramon D. Towards a nosology for frontotemporal lobar degenerations-a meta-analysis involving 267 subjects. Neuroimage2007;36(3):497–510.
51. Rohrer JD, Warren JD, Modat M, et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology2009;72(18):1562–1569.
52. Rabinovici GD, Furst AJ, O’Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology2007;68(15):1205–1212.
56. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology1993;43(2):250–260.
Received: Mar 17 2019 Revision requested: July 29 2019 Revision received: Aug 24 2019 Accepted: Aug 27 2019 Published online: Jan 09 2020 Published in print: Jan 2020
Isabela S.Alves, Artur M. N.Coutinho, AnaVieira, Bruno P.Rocha, Ula L.Passos, Vinicius T.Gonçalves, Paulo D. S.Silva, Malia X.Zhan, Paula C.Pinho, Daniel S.Delgado, Marcos F. L.Docema, Hae W.Lee, Bruno A.Policeni, Claudia C.Leite, Maria G. M.Martin, Camila T.Amancio
13 July 2023 | Neuroradiologie Scan, Vol. 13, No. 03